More on SGMT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.7 Score)

Upcoming Events

- Earnings (11/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Sagimet Biosciences (NQ:SGMT)
Delayed: 10.50 +0.24 (2.34%)
Prev. Close $10.26  
Open$10.15 
52 Wk High$ 
52 Wk Low$ 
Day High$10.72 
Day Low$10.15 
P/E N/A  
EPS$ 
Volume752,203 


Aug 25, 2026 07:00 AM Sagimet targets Q4 2026 enrollment for acne drug trial
Aug 25, 2026 07:00 AM Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Aug 17, 2026 04:28 PM Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 17, 2026 04:05 PM Form 4 Sagimet Biosciences Inc. For: Aug 14 Filed by: Kemble George
Aug 14, 2026 04:39 PM Form 144 Sagimet Biosciences Inc. Filed by: Kemble George
Aug 14, 2026 06:14 AM Form SCHEDULE 13G Sagimet Biosciences Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
Aug 14, 2026 04:22 AM Sagimet Biosciences (SGMT) PT Raised to $29 at Citizens on Denifanstat Peak Sales Estimate
Aug 13, 2026 07:05 AM Form 8-K Sagimet Biosciences Inc. For: Aug 13
Aug 13, 2026 07:00 AM Sagimet gets FDA clearance for phase 3 acne trial of denifanstat
Aug 13, 2026 07:00 AM Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
View All Articles

Entities mentioned with SGMT

View All Entities